You have 1 action to finish to complete your account. Customize your experience by selecting your interests on the Personalization page
No matches
Dermatology

How Does Protective Type 2 Immunity Become Harmful Type 2 Inflammation?

In this video from the March 2025 ADVENT symposium in Orlando, Florida, Dr. Eric Simpson discusses how protective type 2 immunity can become dysregulated, leading to harmful type 2 inflammation. The associated inflammatory process can contribute to the pathophysiology of several dermatological diseases, including AD, PN, CSU, and BP.
Eric Simpson
MD
Eric Simpson

Learning objectives

  • Discuss the evolution of type 2 immunity and the factors that may contribute to its dysregulation in modern populations
  • Explore how type 2 immune cells and mediators drive both protective responses and pathological inflammation, leading to diverse clinical manifestations in the skin
  • Examine the shared and distinct mechanisms of type 2 inflammation in AD, PN, CSU, and BP
Tags
expert insightssymposiummechanism of disease
MAT-GLB-2501638 – 1.0 – 03/2025

About this expert

Dermatology

Eric Simpson

MD

Professor of Dermatology, School of Medicine, Oregon Health & Science University, Portland, US

See author’s profile
Eric Simpson

Related resources

The Emerging Paradigm of Atopic Dermatitis as a Lifelong Predisposition to Episodic Skin Lesions
Dermatology
Infographic

The Emerging Paradigm of Atopic Dermatitis as a Lifelong Predisposition to Episodic Skin Lesions

Expert Case Series: What is the Role of Type 2 Inflammation in Skin Barrier Dysfunction Commonly Observed in Atopic Dermatitis?
Dermatology
interactivity

Expert Case Series: What is the Role of Type 2 Inflammation in Skin Barrier Dysfunction Commonly Observed in Atopic Dermatitis?

AD and PN: Commonalities and Differences – A Case Study
Dermatology
expert video

AD and PN: Commonalities and Differences – A Case Study

Challenges Faced by Dermatologists When Managing Atopic Dermatitis in Children
Dermatology
expert video

Challenges Faced by Dermatologists When Managing Atopic Dermatitis in Children

Beyond the Signs ​and Symptoms: ​The Developmental Burden of AD in Children
Dermatology
expert video

Beyond the Signs ​and Symptoms: ​The Developmental Burden of AD in Children

Challenges Faced by Dermatologists When Managing Atopic Dermatitis in Children - Expert Interview
Dermatology
expert video

Challenges Faced by Dermatologists When Managing Atopic Dermatitis in Children - Expert Interview

New Perspectives in Understanding the Pathophysiology of Atopic Dermatitis in Children - Expert Interview
Dermatology
expert video

New Perspectives in Understanding the Pathophysiology of Atopic Dermatitis in Children - Expert Interview

Practical Considerations for the Management of Children With Moderate-to-severe Atopic Dermatitis - Expert Interview
Dermatology
expert video

Practical Considerations for the Management of Children With Moderate-to-severe Atopic Dermatitis - Expert Interview

Skin Barrier, Neuroimmune Axis, and Type 2 Inflammation in Atopic Dermatitis - Q&As
Dermatology
expert video

Skin Barrier, Neuroimmune Axis, and Type 2 Inflammation in Atopic Dermatitis - Q&As

Immune System, Microbiome and Neuroimmune Crosstalk in the Skin: Implications for AD
Dermatology
expert video

Immune System, Microbiome and Neuroimmune Crosstalk in the Skin: Implications for AD

Importance of Barrier Dysfunction in Driving AD Pathophysiology
Dermatology
expert video

Importance of Barrier Dysfunction in Driving AD Pathophysiology

Role of Type 2 Inflammation in Chronic Inflammatory Diseases
Dermatology
expert video

Role of Type 2 Inflammation in Chronic Inflammatory Diseases

Skin Barrier, Neuroimmune Axis, and Type 2 Inflammation in Atopic Dermatitis
Dermatology
expert video

Skin Barrier, Neuroimmune Axis, and Type 2 Inflammation in Atopic Dermatitis

Targeted Therapies for Children With Atopic Dermatitis - Expert Interview
Dermatology
expert video

Targeted Therapies for Children With Atopic Dermatitis - Expert Interview

The Disease Burden of AD in Children and the Impact of Type 2 Comorbidities 
Dermatology
expert video

The Disease Burden of AD in Children and the Impact of Type 2 Comorbidities 

Type 2 Inflammation Alters the Structure and Function of the Skin in Atopic Dermatitis Interview
Dermatology
expert video

Type 2 Inflammation Alters the Structure and Function of the Skin in Atopic Dermatitis Interview

Type 2 Inflammation Alters the Structure and Function of the Skin in AD
Dermatology
expert video

Type 2 Inflammation Alters the Structure and Function of the Skin in AD

Atopic Dermatitis and Prurigo Nodularis: Distinct skin diseases with shared characteristics
Dermatology
Infographic

Atopic Dermatitis and Prurigo Nodularis: Distinct skin diseases with shared characteristics

Skin Barrier Dysfunction and Type 2 Inflammation in Atopic Dermatitis
Dermatology
videoanimation

Skin Barrier Dysfunction and Type 2 Inflammation in Atopic Dermatitis

What is Early Intervention in AD?
Dermatology
expert video

What is Early Intervention in AD?

Disease Modification in AD
Dermatology
expert video

Disease Modification in AD

Systemic Inflammation in AD – Beyond the Skin
Dermatology
expert video

Systemic Inflammation in AD – Beyond the Skin

Dysbiosis, Skin Infections, and Itch
Dermatology
expert video

Dysbiosis, Skin Infections, and Itch

Skin Barrier Dysfunction in AD
Dermatology
expert video

Skin Barrier Dysfunction in AD

Early Intervention and the Potential for Disease Modification in Children With AD
Dermatology
expert video

Early Intervention and the Potential for Disease Modification in Children With AD

Emerging Data on Advanced Systemic Treatments for Children With AD
Dermatology
expert video

Emerging Data on Advanced Systemic Treatments for Children With AD

Within and Beyond the Skin: New Perspectives on the Role of Type 2 Inflammation in AD
Dermatology
expert video

Within and Beyond the Skin: New Perspectives on the Role of Type 2 Inflammation in AD

The Role of Type 2 Inflammation in Skin Barrier Dysfunction in Atopic Dermatitis
Dermatology
expert video

The Role of Type 2 Inflammation in Skin Barrier Dysfunction in Atopic Dermatitis

The Impact of Skin Dysbiosis on Atopic Dermatitis
Dermatology
expert video

The Impact of Skin Dysbiosis on Atopic Dermatitis

The Association Between Epidermal Barrier Dysfunction and S. aureus Colonization in Atopic Dermatitis
Dermatology
expert video

The Association Between Epidermal Barrier Dysfunction and S. aureus Colonization in Atopic Dermatitis

The Multidimensional Impact of Atopic Dermatitis on Children and Their Caregivers
Dermatology
expert video

The Multidimensional Impact of Atopic Dermatitis on Children and Their Caregivers

Barrier Tight Junction Disruption in Atopic Dermatitis
Dermatology
expert video

Barrier Tight Junction Disruption in Atopic Dermatitis

The Burden of Atopic Dermatitis in Children – Daily Pruritis and Sleep Disturbance 
Dermatology
expert video

The Burden of Atopic Dermatitis in Children – Daily Pruritis and Sleep Disturbance 

The Burden of Atopic Dermatitis in Children – Bullying in School
Dermatology
expert video

The Burden of Atopic Dermatitis in Children – Bullying in School

The Burden of Atopic Dermatitis in Children – Skin Infections and More Severe Disease
Dermatology
expert video

The Burden of Atopic Dermatitis in Children – Skin Infections and More Severe Disease

The Burden of Atopic Dermatitis in Children – Identifying Persistent Disease
Dermatology
expert video

The Burden of Atopic Dermatitis in Children – Identifying Persistent Disease

The Burden of Atopic Dermatitis in Children – The Impact of Persistent Disease
Dermatology
expert video

The Burden of Atopic Dermatitis in Children – The Impact of Persistent Disease

The Role of Epithelial Barrier Components in AD: Insights and Implications
Dermatology
expert video

The Role of Epithelial Barrier Components in AD: Insights and Implications

The Implications of Sweat Duct Dysfunction and the Microbial Dysbiosis in AD
Dermatology
expert video

The Implications of Sweat Duct Dysfunction and the Microbial Dysbiosis in AD

The Potential Impact of Early Intervention in Atopic Dermatitis in Children
Dermatology
expert video

The Potential Impact of Early Intervention in Atopic Dermatitis in Children

Evaluating the Responses to Biologic Therapies in Children With Atopic Dermatitis
Dermatology
expert video

Evaluating the Responses to Biologic Therapies in Children With Atopic Dermatitis

Managing Injection Pain in Children
Dermatology
expert video

Managing Injection Pain in Children

Diagnostic Considerations: Coexistence, and Distinctions of AD & PN
Dermatology
expert video

Diagnostic Considerations: Coexistence, and Distinctions of AD & PN

Key Type 2 Cytokines Impact Skin Structural Proteins in Atopic Dermatitis
Dermatology
expert video

Key Type 2 Cytokines Impact Skin Structural Proteins in Atopic Dermatitis

The Role of Biomarkers in Clinical Decision-Making in Atopic Dermatitis
Dermatology
expert video

The Role of Biomarkers in Clinical Decision-Making in Atopic Dermatitis

The Role of Type 2 Inflammation in Atopic Dermatitis
Dermatology
expert video

The Role of Type 2 Inflammation in Atopic Dermatitis

Atopic Dermatitis in Children: Can Early Therapeutic Intervention Shape Disease Course?
Dermatology
expert video

Atopic Dermatitis in Children: Can Early Therapeutic Intervention Shape Disease Course?

High Burden of Atopic Dermatitis in Children
Dermatology
expert video

High Burden of Atopic Dermatitis in Children

Atopic Dermatitis Leads to Sleep Disruption for Children and Their Caregivers
Dermatology
expert video

Atopic Dermatitis Leads to Sleep Disruption for Children and Their Caregivers

Most Children With Atopic Dermatitis Have Uncontrolled Disease
Dermatology
expert video

Most Children With Atopic Dermatitis Have Uncontrolled Disease

ADVENT is a global medical education non-promotional program by Sanofi and Regeneron. This website is intended only for duly authenticated healthcare professionals in Algeria, Argentina, Australia, Austria, Bahrain, Belgium, Brazil, Bulgaria, Canada, Chile, China, Colombia, Costa Rica, Croatia, Czech Republic, Denmark, Dominican Republic, Ecuador, Egypt, Estonia, Finland, France, Germany, Greece, Guatemala, Hong Kong, Hungary, Iceland, India, Israel, Italy, Japan, Kuwait, Latvia, Lebanon, Lithuania, Macau, Malaysia, Norway, Oman, Panama, Peru, Poland, Portugal, Qatar, Romania, Saudi Arabia, Singapore, Slovenia, South Africa, South Korea, Spain, Sudan, Sweden, Switzerland, Taiwan, Thailand, The Netherlands, Turkey, United Arab Emirates, or the United States of America.

For healthcare professionals in Algeria: Please read the additional Terms of Use.

Sanofi | Regeneron Logo

© 2025 Sanofi and Regeneron Pharmaceuticals, Inc.

All rights reserved.
MAT-GLB-2302957 v3.0 11/2023

All Rights Reserved.

Sanofi and Regeneron are global leaders in pharmaceutical development, each with a long history of supporting frontline physicians to improve human health and reduce the burden of disease. Driven by the same commitment to patients and their families, Sanofi and Regeneron have partnered to take on type 2 inflammation and the range of chronic conditions in which excessive inflammation plays a role.

Country/region: IndiaChange country/region